BIOTECH ASSISTANT / FIELD NOTES

Intellia reports completed MAGNITUDE-2 enrollment and advances launch preparations

Company / institutional announcement · Intellia Therapeutics

Source published: 2026-11-05 · Event / reporting date: 2026-11-05

Site published: 2026-11-06 · Updated: 2026-11-06

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Intellia's third-quarter update reports completed enrollment in the Phase 3 MAGNITUDE-2 trial of nexiguran ziclumeran for hereditary ATTR amyloidosis with polyneuropathy, exceeding the target of 60 randomized patients. The company also described commercial preparations for lonvoguran ziclumeran in hereditary angioedema, ahead of its March 10, 2027 FDA target action date. Approval remains pending.

Why it may matter

Analysis: Late-stage enrollment and launch readiness may increase demand for scalable delivery, analytical characterization, and long-term safety monitoring capabilities.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

In Vivo Cell Engineering & Gene Editing

Related updates

2026-11-05Precision BioSciences / Business Wire

Safety board supports further PBGENE-DMD dosing after first patient's eight-week review

Precision BioSciences said an independent safety board endorsed additional dosing in the Phase 1/2 FUNCTION-DMD study after reviewing the first PBGENE-DMD recipient's eight-week observation period. No serious adverse events or adverse events of special interest were reported in that patient. The AAV-delivered gene-editing program remains investigational; this single-patient review does not establish efficacy or broader safety.

In Vivo Cell Engineering & Gene Editing Ask AI ↗

2026-11-05Precision BioSciences / Business Wire

Precision reports new ELIMINATE-B gene-editing data and plans Phase 2

Precision BioSciences reported updated PBGENE-HBV Phase 1 data covering 25 patients and 59 administrations. The company described pgRNA loss and liver-biopsy evidence of cccDNA reduction at the expected go-forward dose of 0.4 mg/kg, with no dose-limiting toxicities reported. It plans Phase 2 evaluation, including assessment after nucleos(t)ide analog withdrawal; viral cure has not been established.

In Vivo Cell Engineering & Gene Editing Ask AI ↗

2026-11-04Nature

Cancer-selective frameshifting circuits show preclinical activity with systemic AAV9 delivery

A Nature study describes FAST gene circuits that exploit cancer-associated ribosomal frameshifting to conditionally express gasdermin D and trigger pyroptosis. According to the original abstract, systemic AAV9 delivery produced tumor regression and immune activation in mouse colorectal and pancreatic cancer models, with synergy alongside checkpoint blockade. These are cell and animal findings, not human clinical evidence.

In Vivo Cell Engineering & Gene Editing Ask AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗